Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24236518 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL20721135 | 0.76 | — | — | |
| SCHEMBL19630163 | 0.75 | — | — | |
| SCHEMBL23104822 | 0.75 | — | — | |
| Fluoride SCHEMBL20875142 | 0.74 | — | — | |
| SCHEMBL17404495 | 0.73 | — | — | |
| SCHEMBL3431977 | 0.73 | — | — | |
| SCHEMBL18305982 | 0.72 | — | — | |
| SCHEMBL14136770 | 0.72 | — | — | |
| SCHEMBL21064083 | 0.71 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2022-03-10 | — | — | US | disclosed |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2021-12-14 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | disclosed |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2017-11-23 | — | — | US | disclosed |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2017-11-23 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | KDM4E 2151/4885L3MBTL1 1873/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | KDM4E 4070/4885L3MBTL1 2970/4885 |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, SMN1; SMN2 | KDM4E 2381/4885L3MBTL1 1389/4885 |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | KDM4E 4779/4885L3MBTL1 3075/4885 |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | KDM4E 4659/4885L3MBTL1 2150/4885 |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CYP1A2, CYP3A5, UGT1A1 | KDM4E 2151/4885L3MBTL1 1873/4885 |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | KDM4E 752/4885L3MBTL1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.